(Reuters) – The U.S. Food and Drug Administration on Thursday approved a sublingual film from Sunovion Pharmaceuticals Inc, a unit of Japan-based Sumitomo Dainippon, for the treatment of “off” episodes in patients with Parkinson’s disease, according to a label published by the agency.
Parkinson’s disease is a nervous system disorder in which patients suffer from motor fluctuations which oscillate between “off” times, a state of decreased mobility, and “on” times, or periods when the medication is working and symptoms are controlled. (https://bit.ly/2Xklr2A)
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri)
